Toxicity-attenuated mesoporous silica Schiff-base bonded anticancer drug complexes for chemotherapy of drug resistant cancer.

Abstract

Multidrug resistance (MDR), evoked by improper chemotherapeutic practices, poses a serious threat to public health, which leads to increased medical burdens and weakened curative effects. Taking advantage of the enhanced pharmaceutical effect of Schiff base compounds, an aldehyde-modified mesoporous silica SBA-15 (CHO-SBA-15)-bonded anticancer drug combined with doxorubicin hydrochloride (DOX) was synthesized via a Schiff base reaction. Due to the acid-sensitive imine bonds formed between CHO-SBA-15 and DOX, the as-prepared nanocomposites exhibited pH-responsive drug releasing behaviours, resulting in a more enhanced cytotoxic effect on DOX-resistant tumour cells than that of free drugs. Notably, the in vivo studies indicated that mice treated with CHO-SBA-15/DOX composites evidently showed more attenuated systemic toxicity than the free drug molecules. The siliceous mesopore Schiff base-bonded anticancer drug nanocomposite, with minimal chemical modifications, provides a simplified yet efficient therapeutic nanoplatform to deal with drug-resistant cancer.

• Authors: Ling Cai, Ping Zhu, Fei Huan, Jun Wang, Liuzhu Zhou, Huijun Jiang, Minghui Ji, Jin Chen
• Journal: Colloids and surfaces. B, Biointerfaces (Colloids Surf B Biointerfaces) Vol. 205 Pg. 111839 (Sep 2021) ISSN: 1873-4367 [Electronic] Netherlands
• PMID: 34022700 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Antineoplastic Agents
• Drug Carriers
• Schiff Bases
• Silicon Dioxide
• Doxorubicin

Topics

• Animals
• Antineoplastic Agents (pharmacology, therapeutic use)
• Doxorubicin (pharmacology)
• Drug Carriers
• Drug Liberation
• Mice
• Nanoparticles
• Neoplasms (drug therapy)
• Porosity
• Schiff Bases
• Silicon Dioxide